Advanced search
1 file | 795.46 KB

Butyricicoccus pullicaecorum in inflammatory bowel disease

(2013) GUT. 62(12). p.1745-1752
Author
Organization
Project
SBO-100016
Abstract
OBJECTIVE: Many species within the phylum Firmicutes are thought to exert anti-inflammatory effects. We quantified bacteria belonging to the genus Butyricicoccus in stools of patients with ulcerative colitis (UC) and Crohn's disease (CD). We evaluated the effect of Butyricicoccus pullicaecorum in a rat colitis model and analysed the ability to prevent cytokine-induced increases in epithelial permeability. DESIGN: A genus-specific quantitative PCR was used for quantification of Butyricicoccus in stools from patients with UC or CD and healthy subjects. The effect of B pullicaecorum on trinitrobenzenesulfonic (TNBS)-induced colitis was assessed and the effect of B pullicaecorum culture supernatant on epithelial barrier function was investigated in vitro. RESULTS: The average number of Butyricicoccus in stools from patients with UC and CD in active (UC: 8.61 log10/g stool; CD: 6.58 log10/g stool) and remission phase (UC: 8.69 log10/g stool; CD: 8.38 log10/g stool) was significantly lower compared with healthy subjects (9.32 log10/g stool) and correlated with disease activity in CD. Oral administration of B pullicaecorum resulted in a significant protective effect based on macroscopic and histological criteria and decreased intestinal myeloperoxidase (MPO), tumour necrosis factor α (TNFα) and interleukin (IL)-12 levels. Supernatant of B pullicaecorum prevented the loss of transepithelial resistance (TER) and the increase in IL-8 secretion induced by TNFα and interferon γ (IFN gamma) in a Caco-2 cell model. CONCLUSIONS: Patients with inflammatory bowel disease have lower numbers of Butyricicoccus bacteria in their stools. Administration of B pullicaecorum attenuates TNBS-induced colitis in rats and supernatant of B pullicaecorum cultures strengthens the epithelial barrier function by increasing the TER.
Keywords
INHIBITION, DIVERSITY, EXPRESSION, COLONIC-MUCOSA, BUTYRATE ENEMAS, DISTAL ULCERATIVE-COLITIS, KAPPA-B ACTIVATION, IBD, TNBS, Butyricicoccus, 5-AMINOSALICYLIC ACID, CROHNS-DISEASE, GUT MICROBIOTA

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 795.46 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Eeckhaut, Venessa, Kathleen Machiels, Clémentine Perrier, Carlos Romero, Sofie Maes, Bram Flahou, Marjan Steppe, et al. 2013. “Butyricicoccus Pullicaecorum in Inflammatory Bowel Disease.” GUT 62 (12): 1745–1752.
APA
Eeckhaut, V., Machiels, K., Perrier, C., Romero, C., Maes, S., Flahou, B., Steppe, M., et al. (2013). Butyricicoccus pullicaecorum in inflammatory bowel disease. GUT, 62(12), 1745–1752.
Vancouver
1.
Eeckhaut V, Machiels K, Perrier C, Romero C, Maes S, Flahou B, et al. Butyricicoccus pullicaecorum in inflammatory bowel disease. GUT. 2013;62(12):1745–52.
MLA
Eeckhaut, Venessa, Kathleen Machiels, Clémentine Perrier, et al. “Butyricicoccus Pullicaecorum in Inflammatory Bowel Disease.” GUT 62.12 (2013): 1745–1752. Print.
@article{3093310,
  abstract     = {OBJECTIVE: Many species within the phylum Firmicutes are thought to exert anti-inflammatory effects. We quantified bacteria belonging to the genus Butyricicoccus in stools of patients with ulcerative colitis (UC) and Crohn's disease (CD). We evaluated the effect of Butyricicoccus pullicaecorum in a rat colitis model and analysed the ability to prevent cytokine-induced increases in epithelial permeability.
DESIGN: A genus-specific quantitative PCR was used for quantification of Butyricicoccus in stools from patients with UC or CD and healthy subjects. The effect of B pullicaecorum on trinitrobenzenesulfonic (TNBS)-induced colitis was assessed and the effect of B pullicaecorum culture supernatant on epithelial barrier function was investigated in vitro.
RESULTS: The average number of Butyricicoccus in stools from patients with UC and CD in active (UC: 8.61 log10/g stool; CD: 6.58 log10/g stool) and remission phase (UC: 8.69 log10/g stool; CD: 8.38 log10/g stool) was significantly lower compared with healthy subjects (9.32 log10/g stool) and correlated with disease activity in CD. Oral administration of B pullicaecorum resulted in a significant protective effect based on macroscopic and histological criteria and decreased intestinal myeloperoxidase (MPO), tumour necrosis factor \ensuremath{\alpha} (TNF\ensuremath{\alpha}) and interleukin (IL)-12 levels. Supernatant of B pullicaecorum prevented the loss of transepithelial resistance (TER) and the increase in IL-8 secretion induced by TNF\ensuremath{\alpha} and interferon \ensuremath{\gamma} (IFN gamma) in a Caco-2 cell model.
CONCLUSIONS: Patients with inflammatory bowel disease have lower numbers of Butyricicoccus bacteria in their stools. Administration of B pullicaecorum attenuates TNBS-induced colitis in rats and supernatant of B pullicaecorum cultures strengthens the epithelial barrier function by increasing the TER.},
  author       = {Eeckhaut, Venessa and Machiels, Kathleen and Perrier, Cl{\'e}mentine and Romero, Carlos and Maes, Sofie and Flahou, Bram and Steppe, Marjan and Haesebrouck, Freddy and Sas, Benedikt and Ducatelle, Richard and Vermeire, Severine and Van Immerseel, Filip},
  issn         = {0017-5749},
  journal      = {GUT},
  keyword      = {INHIBITION,DIVERSITY,EXPRESSION,COLONIC-MUCOSA,BUTYRATE ENEMAS,DISTAL ULCERATIVE-COLITIS,KAPPA-B ACTIVATION,IBD,TNBS,Butyricicoccus,5-AMINOSALICYLIC ACID,CROHNS-DISEASE,GUT MICROBIOTA},
  language     = {eng},
  number       = {12},
  pages        = {1745--1752},
  title        = {Butyricicoccus pullicaecorum in inflammatory bowel disease},
  url          = {http://dx.doi.org/10.1136/gutjnl-2012-303611},
  volume       = {62},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: